PT97615A - Metodo para atingir um efeito terapeutico sinergistico com composicoes terapeuticas contendo pelo menos dois agentes terapeuticos seleccionados a partir de um inibidor de renina, um inibidor de enzima de conversao de angiotensina i e um antagonista de angiotensina ii - Google Patents

Metodo para atingir um efeito terapeutico sinergistico com composicoes terapeuticas contendo pelo menos dois agentes terapeuticos seleccionados a partir de um inibidor de renina, um inibidor de enzima de conversao de angiotensina i e um antagonista de angiotensina ii

Info

Publication number
PT97615A
PT97615A PT97615A PT9761591A PT97615A PT 97615 A PT97615 A PT 97615A PT 97615 A PT97615 A PT 97615A PT 9761591 A PT9761591 A PT 9761591A PT 97615 A PT97615 A PT 97615A
Authority
PT
Portugal
Prior art keywords
angiotensin
therapeutic
inhibitor
conversation
antagonist
Prior art date
Application number
PT97615A
Other languages
English (en)
Other versions
PT97615B (pt
Inventor
Anthony Andrea Fossa
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24080550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT97615(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of PT97615A publication Critical patent/PT97615A/pt
Publication of PT97615B publication Critical patent/PT97615B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT97615A 1990-05-11 1991-05-09 Metodo para atingir um efeito terapeutico sinergistico com composicoes terapeuticas contendo pelo menos dois agentes terapeuticos seleccionados a partir de um inibidor de renina, um inibidor de enzima de conversao de angiotensina i e um antagonista de angiotensina ii PT97615B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52236090A 1990-05-11 1990-05-11

Publications (2)

Publication Number Publication Date
PT97615A true PT97615A (pt) 1992-03-31
PT97615B PT97615B (pt) 1998-08-31

Family

ID=24080550

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97615A PT97615B (pt) 1990-05-11 1991-05-09 Metodo para atingir um efeito terapeutico sinergistico com composicoes terapeuticas contendo pelo menos dois agentes terapeuticos seleccionados a partir de um inibidor de renina, um inibidor de enzima de conversao de angiotensina i e um antagonista de angiotensina ii

Country Status (34)

Country Link
US (2) US6716875B1 (pt)
EP (1) EP0527879B1 (pt)
JP (2) JPH0729938B2 (pt)
KR (1) KR970005839B1 (pt)
CN (7) CN101156949A (pt)
AP (1) AP240A (pt)
AT (1) ATE148632T1 (pt)
AU (1) AU653724B2 (pt)
BG (1) BG61831B1 (pt)
BR (1) BR9106438A (pt)
CA (1) CA2081564C (pt)
DE (1) DE69124598T2 (pt)
DK (1) DK0527879T3 (pt)
EG (1) EG19648A (pt)
ES (1) ES2097208T3 (pt)
GR (1) GR3022997T3 (pt)
GT (1) GT199100032A (pt)
HK (1) HK1094148A1 (pt)
HU (1) HU227346B1 (pt)
IE (1) IE911592A1 (pt)
IL (1) IL98055A (pt)
IS (1) IS2042B (pt)
MA (1) MA22150A1 (pt)
MY (1) MY114347A (pt)
NO (1) NO924321L (pt)
NZ (1) NZ238118A (pt)
PE (1) PE30891A1 (pt)
PT (1) PT97615B (pt)
RO (1) RO115786B1 (pt)
RU (1) RU2147875C1 (pt)
TW (1) TW203553B (pt)
WO (1) WO1991017771A1 (pt)
YU (1) YU49094B (pt)
ZA (1) ZA913539B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970005839B1 (ko) * 1990-05-11 1997-04-21 화이자 인코포레이티드 상승 치료효과를 얻기 위한 조성물 및 방법
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists
DE4340437C1 (de) * 1993-11-27 1995-05-24 Karla Dr Lehmann Verwendung von Lithiumverbindungen zur Behandlung von Herzinsuffizienz einschließlich ihrer Folgeerkrankungen
CN1181019A (zh) * 1995-04-07 1998-05-06 诺瓦蒂斯有限公司 含有贝那普利或贝那普利拉和维沙坦的药物组合物
EP0835106A4 (en) * 1995-06-30 1998-09-30 Merck & Co Inc METHOD FOR TREATING KIDNEY DISEASES USING AN ACE INHIBITOR AND AII ANTAGONIST
CA2577233C (en) * 1996-04-05 2009-08-18 Takeda Pharmaceutical Company Limited Pharmaceutical composition containing angiotensin ii antagonist
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
CA2257946A1 (en) * 1996-06-24 1997-12-31 Merck & Co., Inc. A composition of enalapril and losartan
US6248724B1 (en) 1997-09-25 2001-06-19 University Of Florida Antisense oligonucleotide compositions targeted to angiotensin converting enzyme MRNA and methods of use
DE69808518T2 (de) * 1997-12-23 2003-06-26 Warner Lambert Co Ace hemmer/matrix metalloproteinase hemmer-arzneimittelkombinationen
US6087343A (en) * 1998-09-14 2000-07-11 University Of Florida Antisense oligonucleotides targeted to β-1 adrenoceptor and methods of use
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20060013852A1 (en) * 2002-06-28 2006-01-19 Prescott Margaret F Use of organic compounds
RU2362560C2 (ru) 2003-04-08 2009-07-27 Проджиникс Фармасьютикалз, Инк. Фармацевтическая препаративная форма
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
CA2580862A1 (en) * 2004-10-08 2006-04-20 Novartis Ag Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
AU2006220682B2 (en) * 2005-03-07 2012-05-31 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
CA2682550C (en) 2007-03-29 2016-05-17 Wyeth Peripheral opioid receptor antagonists and uses thereof
US20100305323A1 (en) 2007-03-29 2010-12-02 Smolenskaya Valeriya N Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
PE20090700A1 (es) 2007-03-29 2009-07-13 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
CN102423483A (zh) * 2011-11-24 2012-04-25 西北农林科技大学 一种复方雷米普利纳米乳抗高血压药物
CN114032273B (zh) * 2021-11-17 2024-02-02 山东省科学院生物研究所 一种多功能西洋参水解肽及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US324377A (en) * 1885-08-18 Roller-skate
US4046889A (en) * 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4814342A (en) 1986-10-31 1989-03-21 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
US4895834A (en) * 1986-12-15 1990-01-23 Warner-Lambert Company Renin inhibitors III
US4962105A (en) 1987-10-19 1990-10-09 Ciba-Geigy Corporation Potentiation of antihypertensive effect of ace inhibitors
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
IL91780A (en) 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
KR970005839B1 (ko) * 1990-05-11 1997-04-21 화이자 인코포레이티드 상승 치료효과를 얻기 위한 조성물 및 방법

Also Published As

Publication number Publication date
KR970005839B1 (ko) 1997-04-21
CN1824315B (zh) 2011-01-12
US6716875B1 (en) 2004-04-06
TW203553B (pt) 1993-04-11
AP9100258A0 (en) 1991-07-31
CN1307901A (zh) 2001-08-15
JPH0748280A (ja) 1995-02-21
IS2042B (is) 2005-09-15
ES2097208T3 (es) 1997-04-01
HU9203522D0 (en) 1993-01-28
CN101156949A (zh) 2008-04-09
CA2081564A1 (en) 1991-11-12
NO924321D0 (no) 1992-11-10
US6900234B1 (en) 2005-05-31
EP0527879B1 (en) 1997-02-05
HU227346B1 (en) 2011-04-28
ZA913539B (en) 1992-12-30
JPH0729938B2 (ja) 1995-04-05
GR3022997T3 (en) 1997-07-30
CN1056426A (zh) 1991-11-27
NZ238118A (en) 1997-06-24
YU81991A (sh) 1994-06-24
MY114347A (en) 2002-10-31
BG61831B1 (bg) 1998-07-31
DE69124598T2 (de) 1997-05-28
MA22150A1 (fr) 1991-12-31
BG97068A (bg) 1993-12-24
JP2635291B2 (ja) 1997-07-30
IS3703A7 (is) 1991-11-12
ATE148632T1 (de) 1997-02-15
HUT62804A (en) 1993-06-28
CN1502370A (zh) 2004-06-09
YU49094B (sh) 2003-12-31
DE69124598D1 (de) 1997-03-20
JPH05505618A (ja) 1993-08-19
CN1915428A (zh) 2007-02-21
IL98055A (en) 1996-10-31
IL98055A0 (en) 1992-06-21
CN100358578C (zh) 2008-01-02
PE30891A1 (es) 1991-11-27
PT97615B (pt) 1998-08-31
EG19648A (en) 1995-09-30
DK0527879T3 (da) 1997-07-14
BR9106438A (pt) 1993-05-18
AP240A (en) 1993-02-18
CA2081564C (en) 1998-02-03
CN1824315A (zh) 2006-08-30
RU2147875C1 (ru) 2000-04-27
WO1991017771A1 (en) 1991-11-28
GT199100032A (es) 1992-10-31
AU7859191A (en) 1991-12-10
IE911592A1 (en) 1991-11-20
CN1879884A (zh) 2006-12-20
RO115786B1 (ro) 2000-06-30
CN1065140C (zh) 2001-05-02
NO924321L (no) 1993-01-08
AU653724B2 (en) 1994-10-13
EP0527879A1 (en) 1993-02-24
HK1094148A1 (en) 2007-03-23

Similar Documents

Publication Publication Date Title
PT97615A (pt) Metodo para atingir um efeito terapeutico sinergistico com composicoes terapeuticas contendo pelo menos dois agentes terapeuticos seleccionados a partir de um inibidor de renina, um inibidor de enzima de conversao de angiotensina i e um antagonista de angiotensina ii
DK0782445T3 (da) Kombination af en opioidantagonist og en selektiv serotoningenoptagelsesinhibitor til behandling af alkoholisme og alkoholafhængighed
EA199800831A1 (ru) Синергетическая гербицидная композиция и способ борьбы с сорняками
ATE350060T1 (de) Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten
BR9608591A (pt) Compostos de imidazol
TR200200205T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
NL300385I1 (nl) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases.
FI971635A0 (fi) Menetelmät neuropeptidiin Y liittyvien tilojen inhiboimiseksi
DE59605572D1 (de) Synergistisches Stabilisatorgemisch
MX340217B (es) Metodo para el tratamietno y bioensayo que involucra el factor de inhibicion de migracion de macrofagos (mif), como un factor de depresion del miocardio, derivado del corazon.
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
DE69613060T2 (de) Synergistische fungizide Zusammensetzungen
DE69431119T2 (de) Inhibitoren des durch sekundäre messenger übertragenen zellsignale
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
ITMI940039A0 (it) Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2
DE60236927D1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
SE0103795D0 (sv) Compounds and method for the treatment of överactive bladder
NZ328198A (en) a pharmaceutical composition containing hydroxyzine and a serotonin uptake inhibitor
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
FI941118A (fi) Bentsyyli-imidatsopyridiinijohdannainen angiotensiini II reseptoriantagonistina
EA199800822A1 (ru) Способ лечения избыточной агрессии
AU8680998A (en) Method for preventing or treating erectile dysfunction by administering an endothelin antagonist
EA200000816A1 (ru) Применение 2-амино-6-трифторметоксибензотиазола для профилактики или лечения дисфункции мозжечка
MX9801683A (es) Composiciones y metodos para controlar hongos perjudiciales.
MX9701529A (es) Uso de (e)-1-[4'-(2-alquilaminoetoxi)fenil]-1-(3'-hidroxifenil)-2-f enilbut-1-enos para inhibir trastornos patologicos.

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19911211

FG3A Patent granted, date of granting

Effective date: 19980526

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20130527